Conduct license negotiations for marketing rights outside Japan once the results of Phase 2 clinical trials can be confirmed
First written in FY2024. 3 of 4 entries say "Reframed", first in FY2025-H1. Latest entry: 2026-10-15.
Chordia Therapeutics moved to the "Worse" side of this theme in 2025.
The whole theme swung hardest in 2022: 1 of 12 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2025-H1ReframedAnnual report
「For CTX-439 and GCN2, in light of the current concentration of R&D resources on rogocekib, the Company is also proactively considering a broad range of possibilities, including early partnering, in addition to advancing R&D internally.」
In addition to negotiating overseas sales rights based on an assessment of the development stage, the Company has expanded its options for CTX-439 and GCN2 to include early partnering in light of the allocation of R&D resources. - FY2024First statedAnnual report
「The Company's basic strategy for business partnerships is to negotiate licenses for sales rights outside Japan when the likelihood increases that a pipeline development program will be marketed as a pharmaceutical product.」
The Company has, for the first time, specified a partnering policy of negotiating rights to sell products outside Japan when Phase 2 clinical trial results become available and pipeline value is expected to increase.